Apogee Therapeutics, Inc. Common Stock (APGE) is a publicly traded Healthcare sector company. As of May 21, 2026, APGE trades at $81.49 with a market cap of $5.94B and a P/E ratio of -19.12. APGE moved +4.09% today. Year to date, APGE is +5.01%; over the trailing twelve months it is +101.76%. Its 52-week range spans $26.20 to $95.32. Analyst consensus is strong buy with an average price target of $122.25. Rallies surfaces APGE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Apogee Therapeutics rises after Q1 2026 results and pipeline update issued May 11: Apogee Therapeutics reported first-quarter 2026 financial results and provided pipeline progress on May 11, 2026. The update reiterated upcoming APEX Phase 2 Part B 16-week data expected in Q2 2026 and guided Phase 3 initiation in atopic dermatitis later in 2026, alongside a $1.3B cash position.
| Metric | Value |
|---|---|
| Price | $81.49 |
| Market Cap | $5.94B |
| P/E Ratio | -19.12 |
| EPS | $-4.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $95.32 |
| 52-Week Low | $26.20 |
| Volume | 382 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-255.84M |
| Gross Margin | 0.00% |
15 analysts cover APGE: 0 strong buy, 13 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $122.25.